Castle Biosciences Inc. (CSTL) Misses Q3 EPS by 7c

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q3 EPS of ($0.47), $0.07 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $23.5 million versus the consensus estimate of $22.97 million.

GUIDANCE:

Castle Biosciences Inc. sees FY2021 revenue of $89-93 million, versus the consensus of $91.8 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• BofA Securities Reiterates Buy Rating on NVIDIA (NVDA)
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance